Loading organizations...
Key people at CF Smackdown: End Cystic Fibrosis This Decade.
CF Smackdown: End Cystic Fibrosis This Decade was founded in 2012 by Stephen Culp (Co-Founder).
CF Smackdown: End Cystic Fibrosis This Decade is a Chattanooga, Tennessee-based nonprofit initiative that combats cystic fibrosis through research collaborations, patient advocacy, and targeted fundraising efforts. Operating primarily as a parent-led advocacy group, the organization focuses on supporting medical breakthroughs and improving clinical outcomes for patients diagnosed with rare cystic fibrosis genotypes. The initiative originally launched as a designated cause on the civic engagement platform Causeway to mobilize community resources and coordinate philanthropic support for specialized disease research. While specific financial metrics regarding total funding raised, operating budgets, or active donor counts remain undisclosed, the group structures its daily operations around community-driven events and direct donations to fund scientific studies. CF Smackdown: End Cystic Fibrosis This Decade was founded around 2012 by Stephen Culp alongside other parents of children affected by the respiratory disease.
CF Smackdown: End Cystic Fibrosis This Decade was founded in 2012 by Stephen Culp (Co-Founder).
Key people at CF Smackdown: End Cystic Fibrosis This Decade.
CF Smackdown: End Cystic Fibrosis This Decade is a grassroots initiative, not a traditional company, dedicated to accelerating a cure for cystic fibrosis (CF) through small seed grants, research support, and community mobilization. Launched by parents of a CF-affected child, it provides funding for projects, papers, and discussions aimed at speeding innovation in CF research and treatment.[3][6][8] Its mission is bold: to help end CF this decade by rallying patients, families, organizations, and researchers to "stand up and do something" against the disease.[3]
Unlike biotech firms developing drugs or investment entities, CF Smackdown operates as a nimble, family-driven effort with a focus on early-stage support. It offers Smackdown Grants—small seed funds—to fuel practical advancements, complementing larger players like the Cystic Fibrosis Foundation (CFF), which uses venture philanthropy for drug development.[2][3][8] This positions it as a catalyst in the CF ecosystem, fostering momentum amid breakthroughs like CFTR modulators (e.g., Trikafta).[1][4]
CF Smackdown emerged from a personal crisis turned action: the founding members, parents of a daughter diagnosed with CF, were "thunderstruck" by the news but pivoted within a year to forge a major research collaboration, add a CF genotype to a clinical trial, and launch the initiative.[3] It first appeared online as a "cause" on Causeway in Chattanooga, TN, around 2012, coinciding with the FDA approval of Kalydeco—the first drug targeting CF's root cause, not just symptoms.[3]
Inspired by accelerating CF breakthroughs post-2012, the Smackdown grew from one family's resolve into a "growing team" emphasizing collective action over individual stories. It humanizes the fight by highlighting patient and family agency, evolving from shock to strategic support amid a landscape transformed by decades of research from groups like the CFF, founded in 1955.[1][3]
CF Smackdown rides the CF treatment revolution, where median life expectancy has doubled in 30 years due to modulator drugs like Kalydeco and Trikafta, addressing genetic root causes via biotech innovation.[1][3][5] It amplifies timing perfected by the CFF's model—early funding de-risking rare disease R&D—now fueling gene therapies (e.g., RCT2100) and small molecules for stubborn mutations like ΔF508.[2][4][5]
Market forces favor it: surging investments (e.g., Sionna's $182M Series C, Vertex's $657M total) and CFF-backed trials create fertile ground for seed grants to bridge gaps in detection, infections, and cures.[4][7] By influencing the ecosystem through collaborations and advocacy, it democratizes progress, echoing how patient-driven efforts accelerated therapies in a field once fatal in childhood.[1][3]
CF Smackdown's next phase likely scales grants amid pipeline booms—targeting gaps in non-modulator-responsive CF cases via gene therapies and infection research, potentially partnering with CFF or biotechs like Sionna.[4][7][8] Trends like mRNA delivery and global equity pushes will shape it, as international collaborators chase universal cures.[2][4]
Its influence could evolve from seed-funder to ecosystem convener, inspiring similar patient-led models if CF nears eradication this decade. Tying back: in a "smackdown" against CF, this initiative proves one family's stand can rally the arena for a knockout.[3]
